SOTIO Biotech Expands Collaboration with Synaffix for Bispecific ADC Development
Synaffix continues to drive innovation in the ADC space. SOTIO Biotech has announced it will be exercising its option with Synaffix BV to develop two bispecific antibody-drug conjugate (ADC) programs.
Boehringer Ingelheim and Synaffix B.V., announced that Boehringer has licensed Synaffix’s ADC technology. This new partnership significantly bolsters Boehringer’s ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s aim of transforming the lives of people with cancer.
Elevation Oncology licenses ADC Technology from Synaffix to drive pipeline expansion
Synaffix B.V. today announces that it has entered into a licensing agreement with Elevation Oncology, Inc., an innovative oncology company dedicated to the discovery and development of selective cancer therapies designed to treat patients with a range of solid tumours that have significant unmet medical needs.
Synaffix licenses metal-free click chemistry technology to Illumina
Synaffix announces it has entered into a licensing agreement with Illumina, a global leader in DNA sequencing and array-based technologies. The agreement grants Illumina access to Synaffix’s patented metal-free click chemistry, for next-generation DNA sequencing applications.
Synaffix licenses ADC technology to BigHat Biosciences
Synaffix BV announces that it has licensed its ADC technology to BigHat Biosciences. BigHat will combine Synaffix technology with its world-class machine learning antibody design platform for the development of a new ADC pipeline programme.
Synaffix’ GlycoConnect platform shows promise for neuromuscular disease treatment
Synaffix’ GlycoConnect platform shows promise for neuromuscular disease treatment.
Ardena and ELDICO Scientific have teamed up, granting Ardena access to ELDICO’s cutting-edge electron diffractometer, the ELDICO ED-1.
SOTIO Enters Licensing Agreement With Synaffix to Expand ADC Pipeline
SOTIO enters agreement with Synaffix. This remarkable agreement provides SOTIO Bio access to ADC technologies, GlycoConnect™, HydraSpace™, and toxSYN™ linker-payloads to expand their #ADC pipeline.
Synaffix entered into licensing agreement with ABL Bio Inc.
Synaffix B.V., a Lonza subsidiary, and ABL Bio, Inc., have joined forces to develop innovative bispecific antibody-drug conjugates (ADCs). Synaffix will handle component manufacturing, receiving upfront payment, milestones, and royalties, while ABL Bio will lead research, development, and commercialization.
This partnership aims to improve cancer cell targeting and therapeutic safety by creating ADCs that bind to two antigens. Lonza, recently acquiring Synaffix, is poised to support clinical production.
Press release: Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
Lonza strengthens its antibody-drug conjugates (ADCs) offering with the acquisition of Synaffix. The integration of Synaffix’s technology platform and R&D capabilities will enhance Lonza’s bioconjugates services, including payload and site-specific linker technology. The companies will expand their Center of Excellence for bioconjugate technology development, focusing on out-licensing bioconjugate technologies for various applications. The acquisition involves a cash consideration of €100 million and additional performance-based consideration. Lonza aims to provide comprehensive services for the discovery, development, and commercialization of novel ADCs, streamlining the path to clinic and market. The move reflects Lonza’s strategy of differentiating through technology and innovation.
Synaffix Announces Expansion of ADC Collaboration with MacroGenics
Synaffix announces the expansion of their collaboration with biopharmaceutical company MacroGenics, Inc., to a value of up to $2.2B plus up to high single-digit royalties. Under this new expanded deal, MacroGenics, Inc. will pursue up to seven of the ADC programs, helping to further contribute towards the transformation of cancer treatment.
Synaffix Named ‘Biotech Company of the Year’ at the LSX European Lifestars Awards
Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces the Company has been awarded ‘Biotech Company of the Year 2022’ at the annual LSX, European Lifestars Awards Ceremony, held on the 14th of November at the Old Billingsgate in London, UK.
or call
Pivot Park – Building RK
Kloosterstraat 9
5349 AB Oss
The Netherlands
+31 (0)412 – 84 60 10
info@pivotpark.com
Pivot Park Exploitatie B.V.
Building OP
Kloosterstraat 9
5349 AB Oss
The Netherlands
10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.
We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.
The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.
Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.
This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.
We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.
Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.
